Kenai Therapeutics, a biotechnology company leveraging induced pluripotent stem cell (iPSC) technology to discover and develop a platform of off-the-shelf neuron replacement therapies for neurological ...

Eli Lilly strengthens its pipeline with AdvanCell for targeted alpha therapies and partners with OliX to advance OLX75016 for ...

BRISBANE, Australia & INDIANAPOLIS--(BUSINESS WIRE)--AdvanCell, a clinical-stage radiopharmaceutical company specializing in targeted alpha therapies, today announced an expansion to the scope and ...

Eli Lilly and Company's impressive Q4 earnings driven by tirzepatide's success, diverse portfolio, and promising pipeline.

Eli Lilly on Thursday suggested that demand for its popular diabetes and weight-loss treatments was not a concern, easing ...

Lilly sigue apostando por su negocio en España. La farmacéutica invertirá un total de 50 millones en su planta de producción ...

La compañía ya ha hecho inversiones previas en su fábrica de Alcobendas con el objetivo de reacondicionar las instalaciones para producir Mounjaro. Más información: Lilly elige su planta de producción ...

With its offering of tirzepatide (branded as Mounjaro and Zepbound), Eli Lilly and Co. (NYSE: LLY) was another key pharma player in this new type of treatment for diabetes and obesity.

Eli Lilly's small pop was due to the latest developments in the lab reported by Novo Nordisk (NYSE: NVO), which, like the U.S. company, is doing brisk business with a weight loss drug: Wegovy ...

It is the largest study ever of the drug category—which includes Novo Nordisk’s GLP-1 treatments Ozempic and Wegovy and Eli Lilly’s dual-action GLP-1/GIP agonists Mounjaro and Zepbound.

Maybe hit the gym ? What you suggesting ? Any tips welcome (prayer emoji).' Lilly first revealed she signed up for the German version of I'm a Celebrity to the Mail's Richard Eden - and ...